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INTRODUCTION
The technical and clinical success rates of endovascular 
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Objective: We wanted to evaluate the status of self-expandable nitinol stents implanted in the P2 and P3 segments of the 
popliteal artery in Korean patients.
Materials and Methods: We retrospectively analyzed 189 consecutive patients who underwent endovascular treatment for 
stenoocclusive lesions in the femoropopliteal artery from July 2003 to March 2009, and 18 patients who underwent stent 
placement in popliteal arterial P2 and P3 segments were fi  nally enrolled. Lesion patency was evaluated by ultrasound or CT 
angiography, and stent fracture was assessed by plain X-rays at 1, 3, 6 and 12 months and annually thereafter. 
Results: At the 1-month follow-up, stent fracture (Type 2) was seen in one limb (up to P3, 1 of 18, 6%) and it was 
identifi  ed in seven limbs at the 3-month follow-up (Type 2, Type 3, Type 4) (n = 1: up to P2; n = 6: P3). At the 6-month 
follow-up, one more fracture (Type 1) (up to P3) was noted. At the 1-year follow-up, there were no additional stent 
fractures. Just four limbs (up to P2) at the 2-year follow-up did not have stent fracture. The primary patency was 94%, 
61% and 44% at 1, 3 and 6 months, respectively, and the group with stent implantation up to P3 had a higher fracture 
rate than that of the group that underwent stenting up to P2 (p < 0.05). 
Conclusion: We suggest that stent placement up to the popliteal arterial P3 segment and over P2 in an Asian population 
can worsen the stent patency owing to stent fracture. It may be necessary to develop a stent design and structure for the 
Asian population that can resist the bending force in the knee joint.
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treatment for stenoocclusive lesions in the femoropopliteal 
artery have reached over 90% due to the improvements in 
the new generation devices (1, 2). However, the long-term 
patency of endovascular treatment remains an unsolved 
issue. In particular, balloon angioplasty alone and stainless-
steel stent placement in the femoropopliteal artery have 
been far from satisfactory, and their primary patencies over 
1-year follow-up are below 60% (3-6). New nitinol stents 
have recently been introduced and these have been proven 
to be superior to balloon angioplasty (7, 8) or a stainless-
steel stent (9) in the superfi  cial femoral artery  in terms of 
the long-term patency. Therefore, endovascular treatment 
with nitinol stents has been widely applied for treating 
femoropopliteal stenoocclusive lesions. However, despite Korean J Radiol 12(2), Mar/Apr 2011 www.kjronline.org 204
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the improved primary patency, stent fracture after the 
deployment of nitinol stents has been recognized as an 
adverse event in the femoropopliteal artery and this can 
be considered as a risk factor for in-stent restenosis and 
reocclusion in a femoropopliteal arterial stent. Although the 
factors that have an infl  uence on femoropopliteal arterial 
stent fracture have not been fully determined, stent fracture 
is believed to occur due to external compression caused 
by muscle activity, by pulsatile blood fl  ow that seems to 
negatively affect the stent structures, by overlapping long 
stents or by mechanical stress at the articulation sites 
(7, 10-13). In particular, popliteal arterial segments P2 
and P3 were previously avoided for stent placement due 
to the articulation sites where a stent could easily be 
bent (13, 14). Yet in practice, it is inevitable that a stent 
is placed in the popliteal arterial segments P2 and P3 
in the case of critical limb ischemia or for bail-out after 
balloon angioplasty. Unfortunately, there has been little 
data regarding the status of stents placed in the popliteal 
arterial segments P2 and P3 and especially in Asian patients 
who often fi  nd it necessary to fully fl  ex the knee joints 
in order to perform routine activities such as kneeling, 
squatting and sitting with both legs crossed. Therefore, the 
purpose of this study is to evaluate the primary patency 
and morphological status of self-expandable nitinol stents 
in the popliteal arteries, and especially the P2 and P3 
segments, in Korean patients. 
MATERIALS AND METHODS
From July 2003 to March 2009, the patients who 
presented to the Departments of Vascular Surgery, Thoracic 
and Cardiovascular Surgery and Orthopedic Surgery 
with intermittent claudication or critical limb ischemia 
(Rutherford category 2-6) in the unilateral or bilateral lower 
extremities underwent CT angiography and Ankle-Brachial 
Index (ABI) measurement. We retrospectively analyzed the 
medical and radiological records of a total of 52 patients 
Table 1. Patients’ and Lesions’ Characteristics























 TASC II D* 6 mm Patent
2 M 66 Secondary Dissection P2 3 TASC II D 6 mm 1 3 month Patent
3 F 74 Secondary Dissection P3 4 TASC II D 6 mm 2 3 month Occlusion
4 M 79 Secondary Dissection P3 2 TASC II D 6 mm 2 3 month Occlusion
5 F 77 Secondary Dissection P3 3 TASC II D 6 mm 3 3 month Occlusion
6 M 69 Secondary Dissection P3 3 TASC II D 6 mm 2 3 month Occlusion
7 F 68 Secondary Dissection P3 5 TASC II D 6 mm 2 6 month Occlusion
8 M 87 Primary Calcifi  cation P3 4 TASC II D 6 mm Multiple 3 month Occlusion
9 M 84 Primary Calcifi  cation P3 3 TASC II D 6 mm 2 1 month Occlusion
10 F 88 Primary Critical limb P3 6 TASC II D 6 mm 2 3 month Occlusion
11 M 68 Primary Critical limb P2 6 TASC II D 6 mm Patent
12 F 66 Primary Critical limb P2 4 TASC II D 6 mm Patent
13 M 71 Primary Critical limb P2 4 TASC II D 6 mm Patent
14 M 68 Primary Critical limb P2 4 TASC II D 6 mm Patent
15 F 69 Primary Critical limb P2 4 TASC II D 6 mm Occlusion
16 M 63 Primary Critical limb P2 4 TASC II D 6 mm Occlusion
17 F 64 Primary Critical limb P2 5 TASC II D 6 mm Patent
18 M 71 Primary Critical limb P2 5 TASC II D 6 mm Patent
Note.— TASC II D* = Chronic total occlusions of common femoral artery or superfi  cial femoral artery (> 20 cm, involving popliteal 
artery). Chronic total occlusion of popliteal artery and proximal trifurcation vessels (25).Korean J Radiol 12(2), Mar/Apr 2011 www.kjronline.org 205
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out of the 189 patients who underwent endovascular 
treatment for femoropopliteal stenoocclusive lesions and 
who had lesions that included the popliteal arterial P2 and 
P3 segments. Twenty-nine limbs had stenosis, 13 limbs 
had an occlusion and 10 limbs had a mixed lesion of both 
stenosis and occlusion. 
All the endovascular treatments were performed in 
the interventional procedure room. Written informed 
consent was obtained from all the study subjects and this 
retrospective study was approved by the Institutional 
Review Board of our institution. Standardized heparin 3000-
5000 IU was administered systematically via the introducer 
sheath at the beginning of the intervention. The indication 
for endovascular treatment for femoropopliteal lesions 
included > 70% of vessel diameter stenosis without infl  ow 
lesions after obtaining the initial diagnostic angiograms of 
the lower limb. The approaches for endovascular treatment 
for the femoropopliteal lesions were determined at the 
operator’s discretion. In general, after inserting a 6-Fr or 
7-Fr sheath, either a 0.035- or a 0.018-inch guide wire 
supported by a differently shaped diagnostic catheter was 
used to cross the lesion. The modalities for endovascular 
treatment were as follows: Primary stent placement was 
performed for the stenoocclusive lesion in the SFA and the 
P1 segment of the popliteal artery. Balloon angioplasty or 
primary stent placement was performed in the popliteal 
arterial P2 and P3 segments and bail-out stenting was 
performed in the patients with unsuccessful primary balloon 
angioplasty, which was defi  ned as a residual stenosis > 
30% or the presence of a fl  ow-limiting dissection. Balloon 
catheters or stents between 5 to 8 mm were used depending 
on the target lesion. A variety of balloon catheters (UT: 
Boston Scientifi  c, Natick, MA; Powerfl  ex: Cordis, Miami, 
FL; Rider: Bolton, Barcelona, Spain) and a single self-
expandable nitinol stent (SMART: Cordis, Miami, FL) were 
used. Dual antiplatelet therapy with aspirin (100 mg/day) 
and clopidogrel (75 mg/day) was started immediately after 
the procedure and this was continued until the 1-month 
follow-up for clopidogrel and the duration of treatment was 
life-long for aspirin.
Stent fracture was defi  ned as clear interruption of the 
stent struts as identifi  ed by plain X-rays from at least two 
projections, with resulting kink or misalignment along 
the axial length of the stent. The morphology of the stent 
fracture was classifi  ed based on a report by Rocha-Singh 
et al. (15). Single-strut fracture was defi  ned as type 1, 
multiple-strut fractures was defi  ned as type 2, stent fracture 
with preserved alignment of the components fractures 
was defi  ned as  type 3, stent fracture with mal-alignment 
of the components fractures was defi  ned as type 4 and 
stent fracture in a trans-axial spiral confi  guration fractures 
was defi  ned as type 5. Lesion patency was evaluated by 
ultrasound or CT angiography, and stent fracture was 
assessed by X-rays at 1, 3, 6 and 12 months and annually 
thereafter. 
Endovascular procedures were considered technically 
successful when all the treated lesions had < 20% residual 
stenosis on completion of angiography. Primary patency 
was defi  ned as the absence of restenosis or occlusion in the 
treated arterial segment. Restenosis was defi  ned as more 
than 50% of the vessel diameter at the treated segments 
as observed on CT angiography or the absence of fl  ow or 
a focal increase of the peak systolic velocity ratio of ≥ 2.5 
on color Duplex ultrasound. Additionally, lesion patency 
according to the type of stent fracture was analyzed, 
and the difference in stent fracture according to stent 
implantation until P2 or until P3 and over P2 was also 
analyzed.
Statistical analysis was performed using SPSS. The Chi-
square test was used to compare the fractures between 
the groups with stent implantation until P2 and until P3 
over P2, P2 with the level of statistical signifi  cance set 
at p values < 0.05. Primary patency was determined by 
performing Kaplan-Meier survival analysis.
RESULTS
Technical success was achieved in 100% of the patients 
who underwent stent placement in the popliteal arterial 
P2 or P3 segments (lesion length: 8-27 cm, mean lesion 
length: 16.5 cm). Forty-one of 52 limbs underwent balloon 
angioplasty to recanalize the stenoocclusive lesions and 
among them, seven limbs underwent stent placement in the 
popliteal arterial P2 and P3 segments for bail-out because 
of inappropriate results of balloon angioplasty such as 
elastic recoil (n = 1) or fl  ow-limiting dissection (n = 6). 
Of them, two limbs underwent bail-out stent placement 
at up to the P2 segment and fi  ve limbs underwent bail-
out stent placement at up to the P3 segment and over 
the P2 segment. The remaining eleven of 52 limbs 
underwent primary stenting in the popliteal arterial P2 
and P3 segments due to severe calcifi  cation or critical limb 
ischemia. Eight limbs underwent stent placement up to the 
P2 segment and 3 limbs underwent stent placement up to Korean J Radiol 12(2), Mar/Apr 2011 www.kjronline.org 206
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the P3 and over the P2 segment.
At the 1-month follow-up, stent fracture (Type 2) was 
seen in one limb that underwent primary stenting up to the 
popliteal arterial P3 segment and over the P2 segment (1 
of 18, 6%); stent fracture was identifi  ed in seven limbs at 
3-month follow-up (Type 1, Type 2, Type 3 and multiple; 
n = 1, n = 4, n = 1 and n = 1, respectively), including one 
of 10 limbs that underwent stent placement up to the P2 
segment (Type 1) (Fig. 1) and six limbs that underwent 
stent placement up to the P3 and over the P2 segment (Type 
2, Type 3 and multiple) (Figs. 2, 3). At the 6-month follow-
up, one more fracture (Type 2) was noted in a residual limb 
that underwent stent placement up to the P3 segment. 
Therefore, all the limbs (n = 8) that underwent stent 
placement up to the popliteal arterial P3 segment had a 
stent fracture at the 6-month follow-up and just one limb (1 
of 10, 10%) had a fracture in the stent placed up to the P2 
segment. At the 1-year follow-up there was no additional 
stent fracture in the 12 limbs that were available for follow-
up. Just four limbs were available for the 2-year follow-up; 
each of them had undergone stent placement up to the P2 
segment and none had developed new stent fracture.
A total of nine limbs experienced overt stent fracture 
during the follow-up period; among them, type 2 fractures 
were identifi  ed in six limbs, type 1 fracture was identifi  ed 
in one limb and type 3 fracture was identifi  ed in one limb. 
One limb had a multiple-type of fracture such as combined 
type 2, type 3 and type 4. The blood fl  ow through the 
stent was completely occluded at the time of detection of 
stent fracture in all the cases of type 2, 3 and 4 fractures, 
but the stent patency was well preserved in the case of 
type 1 fracture. In addition, all the cases that underwent 
stent placement up to the popliteal arterial P3 segment 
and over the P2 segment demonstrated stent fractures with 
Fig. 1. 66-year-old man had symptoms of severe intermittent 
claudication in his left leg. He had chronic total occlusion in distal 
superfi  cial artery and popliteal artery. He underwent stent placement 
up to P2 segment for bail-out after failed balloon angioplasty. Type 1 
stent fracture (arrow) was detected on fl  uoroscopy at 3-month follow-
up.
Fig. 2. 74-year-old man had diabetes with resting pain in his 
right foot. He had chronic total occlusion in distal superfi  cial femoral 
artery and popliteal artery. He underwent stent placement up to P3 
segment for bail-out after failed balloon angioplasty. At 3-month 
follow-up, his symptoms had recurred and type 2 stent fracture (arrows) 
was detected on fl  uoroscopy.Korean J Radiol 12(2), Mar/Apr 2011 www.kjronline.org 207
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complete occlusion of blood fl  ow; however, the cases that 
underwent stent placement up to the P2 segment included 
just one case of stent fracture without evidence of stenosis 
or occlusion. Therefore, the group with stent implantation 
up to the P3 segment had a higher fracture rate than did 
the group that was stented up to the P2 segment (p < 0.05). 
The overall primary patency was 94%, 61% and 44% at 1, 3 
and 6 months, respectively (Table 1).
There were no peri-procedural complications and all of 
the patients were discharged within seven days of their 
procedure.
DISCUSSION
Endovascular intervention in the peripheral circulation 
has proven to be problematic. Although generally effective 
in the relatively large infl  ow arteries of the extracranial 
cerebrovascular and iliac circulations, endovascular 
manipulation of the infrainguinal arteries is technically 
more challenging and the outcome less durable (7, 16-20). 
There are many possible explanations for the discouraging 
results of infrainguinal endovascular intervention. The 
infrainguinal circulation is characterized by long conduits 
with a heavy plaque burden, high impedance outfl  ow 
with low mean fl  ow rates, prolonged fractions of the 
cardiac cycle with stagnant fl  ow and a tendency toward 
exaggerated bending and twisting with skeletal movement 
(21). The latter phenomenon contributes to stent fracture 
of self-expanding stents in the femoropopliteal arteries. 
Indeed, self-expanding stents in the SFA have shown an 
alarming tendency to fracture, with rates as high as 65% 
in one clinical report (22); another recent clinical study of 
40 consecutive patients treated with the Luminexx stent 
documented strut fracture in 28%, with more frequent 
occurrence in the patients who were vigorously active and 
ambulatory (23). There have been many studies of stent 
patency and stent fracture in the femoropopliteal arteries. 
In our study, stent fracture worsened the patency during 
the fi  rst two years, but it did not apparently affect the 
patency beyond two years. Although type 2 stent fracture 
revealed poor outcomes, neither type 1 nor type 3 stent 
fractures affected the primary patency compared with those 
stents without stent fracture (7, 8). In our study, all the 
cases with type 2 stent fractures had complete occlusion 
of blood fl  ow, while good stent patency was identifi  ed with 
type 1 stent fracture; these results were similar to those 
of previous studies. However, contrary to the previous 
studies, the cases of type 3 stent fracture in our study had 
complete occlusion of stent patency, although one case had 
a mixed lesion that included type 2 and type 4 fractures. 
Therefore, this study cannot give us a full answer regarding 
the correlation between stent patency and the types of 
stent fracture because of the small number of type 3 stent 
fractures (n = 2) and the small total number of cases with 
stent fracture (n = 9). 
In general, stent implantation in the femoropopliteal 
arteries has been performed in the SFA and proximal 
popliteal artery (P1 segment), and one study recommended 
that stent implantation be avoided in the middle or distal 
third of the popliteal artery (the P2 and P3 segments) (13). 
While those previous studies observed stent fracture in the 
femoropopliteal arteries, they did not analyze the stent 
status in the bending portion of the popliteal arterial P2 
and P3 segments. In addition, although it is well known 
that stent implantation in the popliteal arterial P2 and P3 
Fig. 3. 87-year-old man had diabetes with resting pain in 
his right foot. He had chronic total occlusion from mid-superfi  cial 
femoral artery to popliteal arterial P3 segment with massive 
calcifi  cations (arrowheads). Therefore, he underwent primary stenting 
there. However, at 3-month follow-up, his symptoms had recurred and 
type 2, 3 and 4 fractures (arrows) were detected on fl  uoroscopy.Korean J Radiol 12(2), Mar/Apr 2011 www.kjronline.org 208
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segments can be considered harmful, it is very diffi  cult to 
fi  nd results regarding the stent structural problems such as 
fracture after implantation in the popliteal arterial P2 and 
P3 segments. Although our study involved a small study 
population, it will be valuable to analyze the stent status in 
the popliteal arterial P2 and P3 segments, which are more 
vulnerable to mechanical forces such as bending than are 
the SFA and the popliteal arterial P1 segment.
Iida et al. (24) suggested in their study that the 
incidence of stent fracture was lower than that observed 
in the FESTO (Femoral Stenting in Obstructions) trial (12), 
and this result may be attributed to the differences of the 
life-styles and physique in the Eastern population. They 
assumed that the body mass index in the patients included 
in that study was approximately 22 kg/m
2 and it may be 
interesting to speculate that stent fracture is adversely 
affected by muscle volume through compression and 
expansion mechanisms. However, that study did not mention 
the stent status in the middle or distal popliteal artery. Full 
fl  exion is often necessary in Asian culture to perform key 
routine activities such as kneeling, squatting and sitting 
with both legs crossed; in response to such demand, efforts 
have been made to achieve greater fl  exion of stents in the 
knee joint of the Asian population than that in the Western 
population. Therefore, we assumed that stent placement 
in the popliteal arterial P2 and P3 segments in the Asian 
population may result in more structural problems of stents, 
such as fracture, than that in the Western population and 
in fact, all of our patients who underwent stent placement 
over P2 and up to the P3 segment of the popliteal artery 
had stent fracture accompanied by complete occlusion. 
Our study has some limitations and shortcomings. First, 
this study was retrospectively conducted. Second, the 
number of cases was few and the follow-up data over six 
months was incomplete. Third, our study did not collect 
data regarding re-intervention in the case of stent fracture 
with complete occlusion of blood fl  ow because all the 
patients refused the second intervention and some of them 
moved to other hospitals. Fourth, only one type of stent 
was used during the period of this study; therefore, it may 
be diffi  cult to apply our results to other stents. Fifth, our 
study did not analyze the clinical symptomatic improvement 
after technically successful stent placement due to the lack 
of medical records regarding this.
In conclusion, we suggest that self-expandable stent 
placement up to the popliteal arterial P3 segment and 
over the P2 segment can worsen the preservation of 
stent patency with a high incidence of stent fracture, and 
especially in the Korean population. It is necessary to 
develop a stent design and structure that can resist the 
bending force in the knee joint.
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